TEL AVIV, Israel and WHITE PLAINS, N.Y., Feb. 20, 2013 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce that its Chief Science Officer, Prof. Sarah Ferber, is scheduled to present at the 6th International Conference on Advanced Technologies & Treatments for Diabetes, to be held February 27 - March 3, 2013 in Paris, France.
Prof. Ferber's presentation will be based on a peer-reviewed and accepted abstract, entitled "Implementation of Advanced Autologous Cell-Based Therapy for Diabetic Patients."
"Results from in-vitro and in-vivo studies of our groundbreaking therapeutic approach using human liver tissues have been promising," said Sav DiPasquale, President and Chief Executive Officer of Orgenesis. "Based on this significant discovery and these findings, we are continuing to progress towards the initiation of the first in-human clinical trials of our diabetes treatment product. We are very pleased to have this opportunity to update diabetes experts and thought leaders on our research within the field of transdifferentiation and the promise those advancements may hold for the treatment of this challenging disease."
About ATTD 2013
ATTD 2013 is an innovative conference that will bring together the world's leading researchers and clinicians for a lively exchange of ideas and information related to the treatment and prevention of diabetes and related illnesses.
Over the last five years, 'ATTD' has become synonymous with top caliber scientific programs that have provided participants with cutting edge research and analysis into the latest developments in diabetes-related technology.
About Orgenesis Inc.
Orgenesis (OTCBB:ORGS) is a development stage company with a novel therapeutic technology that employs a molecular and cellular approach directed at converting a patient's own liver cells into functional insulin producing cells, as a treatment for diabetes. The Company believes that converting the diabetic patient's own tissue into insulin-producing cells overcomes the problem of donor shortage and removes the risk of transplant rejection. If successful, this could mean the end of diabetes, as we now know it. For more information visit: www.orgenesis.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to retain key employees and our ability to finance development or satisfy the rigorous regulatory requirements for new medical procedures. Competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.
On Behalf of the Board
Vered Caplan, Chairperson
CONTACT: Investor Contact: Stephen Kilmer Kilmer Lucas Inc. T: 212-618-6347 email@example.com Media Contact: Leonard Zehr Kilmer Lucas Inc. T: 416-833-9317 firstname.lastname@example.orgSource:Orgenesis Inc.